Re: Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands

Journal of the National Cancer Institute

Volumn 102, Issue 5, 2010, Pages 358-

  Coupe, Veerle M H ^a   Meijer, Chris J L M ^a   Berkhof, Johannes ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

CANCER IMMUNIZATION; COST EFFECTIVENESS ANALYSIS; HUMAN; LETTER; METHODOLOGY; NETHERLANDS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; STATISTICAL MODEL; UTERINE CERVIX CANCER; ALPHAPAPILLOMAVIRUS; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; FEMALE; IMMUNOLOGY; NOTE; PAPILLOMAVIRUS INFECTION; VIROLOGY; VIRUS INFECTION;

ALPHAPAPILLOMAVIRUS; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; HUMANS; NETHERLANDS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; QUALITY-ADJUSTED LIFE YEARS; TUMOR VIRUS INFECTIONS;

EID: 77749254875     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djp372     Document Type: Letter

References (2)

1. De Kok I, Van Ballegooijen M, Habbema JD. cost-effectiveness analysis of human papillo-mavirus vaccination in the netherlands. J Natl Cancer Inst. 2009;101(15):1083-1092.
2. Coupe VM, Van Ginkel J, De Melker HE, Snijders PJ, Meijer CJ, Berkhof J. HPv16/18 vaccination to prevent cervical cancer in The netherlands: model-based cost-effectiveness. Int J Cancer. 2009;124(4):970-978.